Join Alaina and Zarmeen this week as they celebrate Zarmeen's birthday by diving into the recently published report of a phase 2 clinical trial of psilocybin for treatment resistant depression. They go over some background, methodology and results surrounding the study and what it means moving forward. Of course, they also give their interpretations and discuss thoughts about sensationalism, limitations and the things they liked about the study. TW: suicidal ideation and self-injury.

The content of YBOS is the opinion of the authors and does not reflect the opinion of others or author affiliations.